<DOC>
	<DOCNO>NCT01294553</DOCNO>
	<brief_summary>An open label , multi-centre , non-interventional post-marketing surveillance monitor safety and/or efficacy rosiglitazone/metformin administer Korean Diabetic patient accord prescribe information</brief_summary>
	<brief_title>An Open Label , Multi-centre , Non-interventional Post-marketing Surveillance Monitor Safety and/or Efficacy AVANDAMET Between June 2004 January 2010</brief_title>
	<detailed_description>An open label , multi-centre , non-interventional post-marketing surveillance monitor safety and/or efficacy rosiglitazone/metformin administer Korean Diabetic patient accord prescribe information</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion Subjects administer rosiglitazone/metformin adjunct diet exercise treatment type2 diabetes mellitus Subjects investigator believe comply requirement protocol follow administration regimen Subjects administer rosiglitazone/metformin follow locally approve prescribe information Exclusion criterion Subjects previous history hypersensitivity rosiglitazone and/or metformin ingredient Subjects previous history lactic acidosis , renal disease renal dysfunction , hepatic dysfunction , cardiogenic shock , heart failure , myocardial infarction , pulmonary infarction status stomach upset Subjects type 1 diabetes mellitus Subjects acute chronic metabolic acidosis , include diabetic ketoacidosis , without coma Subjects severe infection , pre/post surgery , severe trauma Subjects malnutrition , inanition , emaciation , pituitary insufficiency , adrenal insufficiency Subjects undergo radiologic study involve intravascular administration iodinate contrast material</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>